MX2018004445A - Particulas coloidales para su uso en medicina. - Google Patents

Particulas coloidales para su uso en medicina.

Info

Publication number
MX2018004445A
MX2018004445A MX2018004445A MX2018004445A MX2018004445A MX 2018004445 A MX2018004445 A MX 2018004445A MX 2018004445 A MX2018004445 A MX 2018004445A MX 2018004445 A MX2018004445 A MX 2018004445A MX 2018004445 A MX2018004445 A MX 2018004445A
Authority
MX
Mexico
Prior art keywords
medicine
colloidal particles
composition
contain
active agent
Prior art date
Application number
MX2018004445A
Other languages
English (en)
Inventor
Mayo John
Henry William
Wolf-Garraway Richard
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of MX2018004445A publication Critical patent/MX2018004445A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona una composición que comprende una partícula coloidal que comprende aproximadamente del 0.5 al 20 por ciento en moles de un lípido anfipático derivatizado con un polímero hidrófilo biocompatible para su uso en medicina, en la que dicha composición no contiene ningún agente farmacéuticamente activo.
MX2018004445A 2015-10-14 2016-10-14 Particulas coloidales para su uso en medicina. MX2018004445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518172.0A GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine
PCT/EP2016/074759 WO2017064276A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine

Publications (1)

Publication Number Publication Date
MX2018004445A true MX2018004445A (es) 2018-08-14

Family

ID=55131025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004445A MX2018004445A (es) 2015-10-14 2016-10-14 Particulas coloidales para su uso en medicina.

Country Status (15)

Country Link
US (2) US20190192664A1 (es)
EP (1) EP3362039A1 (es)
JP (1) JP7160678B2 (es)
KR (1) KR20180067616A (es)
CN (1) CN108472246A (es)
AU (1) AU2016336929B2 (es)
BR (1) BR112018007399A2 (es)
CA (1) CA3036111C (es)
EA (1) EA201890703A1 (es)
GB (1) GB201518172D0 (es)
HK (1) HK1256814A1 (es)
IL (1) IL258567A (es)
MX (1) MX2018004445A (es)
SG (2) SG10202010711UA (es)
WO (1) WO2017064276A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202111759D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111758D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2131206T3 (es) 1993-08-06 1999-07-16 Opperbas Holding Bv Un metodo de carga elevada de vesiculas con sustancias biopolimeras.
AU747391B2 (en) 1998-04-27 2002-05-16 Cantab Biopharmaceuticals Patents Limited Pharmaceutical composition comprising factor VIII and neutral liposomes
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU769517B2 (en) 1999-07-14 2004-01-29 Alza Corporation Neutral lipopolymer and liposomal compositions containing same
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
CN1774281B (zh) * 2003-04-15 2010-10-13 奥珀百思控股公司 包含蛋白质和/或多肽以及胶体颗粒的药物组合物
BRPI0612843A2 (pt) * 2005-06-29 2010-11-30 Univ New York State Res Found composição farmacêutica, métodos para fabricar a composição, e, uso de uma formulação
GB2483419B (en) 2009-06-03 2015-04-08 Sequessome Technology Holdings Ltd Formulations for the treatment of deep tissue pain
MX336482B (es) 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
JP2015512927A (ja) 2012-04-16 2015-04-30 カンタブ バイオファーマシューティカルズ パテンツ リミテッド 最適化された皮下治療薬
CA2904184C (en) * 2013-03-08 2021-09-07 Novartis Ag Lipids and lipid compositions for the delivery of active agents

Also Published As

Publication number Publication date
KR20180067616A (ko) 2018-06-20
WO2017064276A1 (en) 2017-04-20
GB201518172D0 (en) 2015-11-25
BR112018007399A2 (pt) 2018-10-16
EA201890703A1 (ru) 2018-11-30
CN108472246A (zh) 2018-08-31
CA3036111A1 (en) 2017-04-20
EP3362039A1 (en) 2018-08-22
IL258567A (en) 2018-05-31
CA3036111C (en) 2023-06-06
US20210093721A1 (en) 2021-04-01
JP2018535952A (ja) 2018-12-06
HK1256814A1 (zh) 2019-10-04
JP7160678B2 (ja) 2022-10-25
SG11201802956RA (en) 2018-05-30
AU2016336929B2 (en) 2022-09-29
AU2016336929A1 (en) 2018-05-10
SG10202010711UA (en) 2020-12-30
US20190192664A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
CY1124380T1 (el) Συστηματα διαβλεννογονιας και διαδερμικης χορηγησης
MY191574A (en) Pharmaceutical compositions comprising meloxicam
EP3861982A3 (en) Intracameral implant for treatment of an ocular condition
MY187540A (en) Compounds active towards bromodomains
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
EP3686184A3 (en) Ionizable compounds and compositions and uses thereof
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
MX2017000041A (es) Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos.
MX2019010852A (es) Nanoparticulas a base de lipidos con estabilidad mejorada.
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
IL270159B (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases
MX2018004445A (es) Particulas coloidales para su uso en medicina.
EP3471699A4 (en) HYBRID MUCO-ADHESIVE DELIVERY SYSTEMS.
WO2016001905A3 (en) Stable liquid ready-to-use injectable formulation of bortezomib
GB2528421A (en) Methods and processes for application of drug delivery polymeric coatings
CA3010981A1 (en) Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
MX2018006226A (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
PH12020550185A1 (en) Semaglutide in medical therapy
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
WO2015054208A8 (en) Injectable compositions
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
WO2019070727A3 (en) Nonviral gene transfer to the suprachoroidal space